EO2401 not checked

Enterome

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase”In the company’s words, NCT04116658 on ClinicalTrials.gov
Tested for
Glioblastoma, Adult, Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Main trialPhase 1/2
“The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.”In the company’s words, NCT04116658 on ClinicalTrials.gov

Other drugs for Glioblastoma, Adult

All 94 drugs for Glioblastoma, Adult

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Completed 4 Mar 2024 First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
Phase 1/2Terminated 2 Oct 2024 A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow EO2401

Following is part of Solo: you see every change to EO2401 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in